TLR4 and cancer: Immunomodulating drugs targeting TLR4 are actively investigated in cancer, where TLR4 persistent activation can induce chronic inflammatory conditions contributing to carcinogenesis, while TLR4 agonists can induce anti-tumor immunity (Awasthi, 2014).